Daniel J. Olson

Has grant

Assistant Professor of Medicine

University of Chicago
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

About

Daniel J. Olson is an Assistant Professor at the University of Chicago, USA. His research focuses on leveraging components of innate immunity, including STING, Batf3 dendritic cells, and CXCR3 ligands, to enhance tumor microenvironments for immunotherapy. Recent publications include studies on the effects of pembrolizumab and ipilimumab in melanoma and their implications following PD-1 antibody failure.

Recent Grants

Grant: Close

Biomarkers of combined PD-1 and CTLA-4 antibody responsiveness after prior PD-1 antibody failure in advanced melanoma

Open Date: 2021-10-01

Close Date: 2023-10-01

Articles (11)

Ewing sarcoma and osteosarcoma constitute 36% of all primary bone cancers. However, these 2 subtypes represent the most commonly diagnosed bone cancer types in the pediatric and adolescent population. Although still largely unknown, certain genetic mutations, rearrangements, and/or predisposition syndromes likely play a role in the pathogenesis of bone cancer. Osteosarcoma may also develop as a direct result of the long-term side effects of radiation therapy. With the implementation of a multimodality approach to treatment, including multiagent neoadjuvant and adjuvant chemotherapy regimens, targeted therapy options, surgery, and radiation, individuals with Ewing sarcoma and osteosarcoma are showing higher cure rates and improved overall survival. The NCCN Guidelines for Bone Cancer provide a consensus and evidence-based framework for the workup, management, and surveillance of local and recurrent/metastatic disease.

Year:

2025

Lung cancer is the leading cause of all cancer-related deaths in the United States and remains a global health challenge. While targeted therapy has revolutionized the treatment landscape of nonsmall cell lung cancer, many patients lack actionable mutations. Immunotherapy, particularly immune checkpoint inhibitors (ICIs), have significantly impacted outcomes in lung cancer in the last decade. Some patients, however, never respond or become refractory to ICIs. Newer therapies aimed at augmenting the immune system and enhancing antitumor effects are currently being explored. Adoptive cell therapy (ACT) employs T cells isolated from either tumors or peripheral blood and often engineers them to effect antitumor immune response. Chimeric antigen receptor T (CAR-T) cell therapy, engineered T cell receptor therapy, and tumor-infiltrating lymphocytes are examples of adoptive cellular therapies. CAR-T cell therapy has been successful in the treatment of hematological malignancies with several CAR products gaining approval in the treatment of refractory blood cancers. The success of ACTs in hematological cancers has fueled research into the role of these therapies in solid cancers including lung cancer. Many trials have had early promising results, with many clinical trials currently enrolling. There are many limitations to the efficacy of ACTs, as well as risks and benefits with the individual subtypes of ACT. With growing knowledge about tumor antigens and more advanced cell engineering, there is potential for ACT to result in durable responses in immunologically “cold” tumors. Here, we review the major subtypes of ACTs, evidence supporting their use in lung cancer, challenges, and future perspectives in ACTs. Additionally, we include T cell engagers and mRNA vaccine studies and potential combinatorial strategies in lung cancer.

Year:

2025

scRNA-seq data from a single patient with tumor biopsy prior to and after dazostinag and pembrolizumab administration following RT. A, UMAP of lymphocytes colored by cell type (left) and sampling time (right). B, Cell type ratio to total lymphocytes in screen and C1D15 samples, with NK and NKT-like cells highlighted in dashed box. C, Hallmark GSEA of upregulated genes in lymphocytes comparing C1D15 with screen samples. D, UMAP of myeloid cells colored based on sampling time (left), and Hallmark GSEA of upregulated genes in myeloid cells comparing C1D15 with screen samples (right). CD, cluster of differentiation; KRAS, Kirsten rat sarcoma virus; mTORC1, mTOR complex 1; NA, not applicable; STAT, signal transducer and activator of transcription; Treg, regulatory T cell.

Year:

2025

A and B, Preclinical antitumor activity and ( C and D ) analysis of tumor immune cells in EMT6 tumor-bearing mice treated with dazostinag following fractionated radiation. α, anti; Gy, gray; mock, mock radiation treatment.

Year:

2025

Pharmacodynamic analysis of STING signature and cytokine production in patients treated with dazostinag and pembrolizumab following radiation. A, STING signature score fold change by dazostinag doses and normalized to cycle 1, 0 hours. Median fold change across 32 patients per dose per time point plotted. B–H, IL6, IFNγ, IP-10, MCP-1, MIP-1α, MIP-1β, and eotaxin-3 cytokines concentration in plasma samples from 21 patients at screening (before radiation) and at 0 and 6 hours after dazostinag administration. Data are shown as the mean fold change (±SEM) normalized to cycle one, 0-hour levels in patients treated with indicated doses of dazostinag and pembrolizumab. CXCL-10, CXC ligand 10.

Year:

2025

Purpose: We present the preclinical rationale and clinical data from a phase 1b trial investigating the STING agonist dazostinag plus pembrolizumab following hypofractionated radiotherapy (RT) in patients with advanced non–small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), or squamous cell carcinoma of the head and neck (SCCHN) whose disease had progressed on prior checkpoint inhibitors (CPI; NCT04879849). Patients and Methods: Eligible patients received radiation (8 Gy × 3 fractions) followed (≥40 hours) by pembrolizumab 200 mg every 3 weeks and dazostinag in escalating doses (0.2–5.0 mg). Primary endpoints were safety and tolerability. Secondary endpoints included preliminary antitumor activity in irradiated and nonirradiated lesions, pharmacokinetic analyses, and pharmacodynamic analyses. Results: Preclinical studies demonstrated tumor control and enhanced intratumoral immune activation in mice treated with dazostinag plus radiation. Thirty-four patients (NSCLC: 15, SCCHN: 10, and TNBC: 9) with a median number of six prior treatments were enrolled. Thirty-three (97.1%) patients reported treatment-emergent adverse events (TEAE), none were dose-limiting toxicities; the most common were fatigue (52.9%), constipation (26.5%), and cough (20.6%). Dazostinag-related TEAEs occurred in 17 patients (50.0%); the most common were fatigue (26.5%), chills (8.8%), diarrhea, arthralgia, and myalgia (5.9% each). Antitumor activity, per RECIST v.1.1, was confirmed in two (7.1%) patients (one complete response and one partial response). Pharmacodynamic analyses indicated activation of STING and IFNγ pathways across multiple dose levels and induced immune responses, consistent with preclinical studies. Conclusions: Dazostinag, combined with pembrolizumab after RT, was well tolerated and demonstrated clinical activity in some patients with advanced/metastatic tumors whose disease had progressed on CPIs. Significance: Dazostinag, an intravenous STING agonist, combined with radiation, demonstrated tumor control and enhanced intratumoral immune activation, preclinically. In phase 1b, dazostinag plus pembrolizumab following RT had a manageable safety profile and provided clinical benefit for some heavily pretreated patients with advanced/metastatic solid tumors whose disease had progressed on CPIs.

Year:

2025

Purpose: We present the preclinical rationale and clinical data from a phase 1b trial investigating the STING agonist dazostinag plus pembrolizumab following hypofractionated radiotherapy (RT) in patients with advanced non–small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), or squamous cell carcinoma of the head and neck (SCCHN) whose disease had progressed on prior checkpoint inhibitors (CPI; NCT04879849). Patients and Methods: Eligible patients received radiation (8 Gy × 3 fractions) followed (≥40 hours) by pembrolizumab 200 mg every 3 weeks and dazostinag in escalating doses (0.2–5.0 mg). Primary endpoints were safety and tolerability. Secondary endpoints included preliminary antitumor activity in irradiated and nonirradiated lesions, pharmacokinetic analyses, and pharmacodynamic analyses. Results: Preclinical studies demonstrated tumor control and enhanced intratumoral immune activation in mice treated with dazostinag plus radiation. Thirty-four patients (NSCLC: 15, SCCHN: 10, and TNBC: 9) with a median number of six prior treatments were enrolled. Thirty-three (97.1%) patients reported treatment-emergent adverse events (TEAE), none were dose-limiting toxicities; the most common were fatigue (52.9%), constipation (26.5%), and cough (20.6%). Dazostinag-related TEAEs occurred in 17 patients (50.0%); the most common were fatigue (26.5%), chills (8.8%), diarrhea, arthralgia, and myalgia (5.9% each). Antitumor activity, per RECIST v.1.1, was confirmed in two (7.1%) patients (one complete response and one partial response). Pharmacodynamic analyses indicated activation of STING and IFNγ pathways across multiple dose levels and induced immune responses, consistent with preclinical studies. Conclusions: Dazostinag, combined with pembrolizumab after RT, was well tolerated and demonstrated clinical activity in some patients with advanced/metastatic tumors whose disease had progressed on CPIs. Significance: Dazostinag, an intravenous STING agonist, combined with radiation, demonstrated tumor control and enhanced intratumoral immune activation, preclinically. In phase 1b, dazostinag plus pembrolizumab following RT had a manageable safety profile and provided clinical benefit for some heavily pretreated patients with advanced/metastatic solid tumors whose disease had progressed on CPIs.

Year:

2025

The authors would like to make the following corrections to their published paper [...]

Year:

2024

Year:

2022

Year:

2022

Year:

2021

Collaborators (6)

Wade T. Iams

-

UNITED STATES
View details

Yuan Yuan

Scripps Research Institute

UNITED STATES
View details

Susan M. Hiniker

Stanford University

UNITED STATES
View details

Michael J. Ferguson

University of Louisville

UNITED STATES
View details

Kwok-Kin Wong

NYU Langone Medical Center

UNITED STATES
View details

Jason J. Luke

-

UNITED STATES
View details